Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Wuhan YZY Biopharma Co., Ltd. has announced the resignation of Dr. Dai Weiguo, an independent non-executive Director and member of the nomination committee, effective from July 30, 2024. The company is now seeking a replacement to comply with the Hong Kong Stock Exchange’s majority rule for independent directors on the nomination committee. The Board has expressed appreciation for Dr. Dai’s contributions and assures there are no disagreements related to his departure.
For further insights into HK:2496 stock, check out TipRanks’ Stock Analysis page.